The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent
Open accessAbstract
Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC 90 ) value of ≤0.25 μg/ml for CF-301. Mature biofilms of coagulase-negative staphylococci, Streptococcus pyogenes , and Streptococcus agalactiae were also sensitive to disruption, with MBEC 90 values ranging from 0.25 to 8 μg/ml. The potency of CF-301 was demonstrated against S. aureus biofilms formed on polystyrene, glass, surgical mesh, and catheters. In catheters, CF-301 removed all biofilm within 1 h and killed all released bacteria by 6 h. Mixed-species biofilms, formed by S. aureus and Staphylococcus epidermidis on several surfaces, were removed by CF-301, as were S. aureus biofilms either enriched for small-colony variants (SCVs) or grown in human synovial fluid. The antibacterial activity of CF-301 was further demonstrated against S. aureus persister cells in exponential-phase and stationary-phase populations. Finally, the antibiofilm activity of CF-301 was greatly improved in combinations with the cell wall hydrolase lysostaphin when tested against a range of S. aureus strains. In all, the data show that CF-301 is highly effective at disrupting biofilms and killing biofilm bacteria, and, as such, it may be an efficient new agent for treating staphylococcal infections with a biofilm component.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies for combating bacterial biofilm infections
Wu, H., Moser, C., Wang, H.-Z., Høiby, N., & Song, Z.-J. (2015) · International Journal of Oral Science · doi:10.1038/ijos.2014.65 · Cited by 925
Tseng, B. S., Zhang, W., Harrison, J. J., Quach, T. P., Song, J. L., Penterman, J., Singh, P. K., Chopp, D. L., Packman, A. I., & Parsek, M. R. (2013) · Environmental Microbiology · doi:10.1111/1462-2920.12155 · Cited by 466 · cited 1×
“antibiotics (10), and biofilm communities will include subpopulations of semidormant persister bacteria (including small-colony variants [SCVs]) with phenotypic tolerance to antibiotics (11).”
BackgroundTherapeutic Potential of Biofilm-Dispersing Enzymes
Kaplan, J. B. (2009) · The International Journal of Artificial Organs · doi:10.1177/039139880903200903 · Cited by 217
Cited by
Staphylococcal Biofilm Development: Structure, Regulation, and Treatment Strategies
Schilcher, K., & Horswill, A. R. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00026-19 · Cited by 706
Otto, M. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0023-2018 · Cited by 381
Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas Jr., C., Mosa, R. A., Viegas, F. P., & Pooe, O. J. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 321
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics
Defraine, V., Fauvart, M., & Michiels, J. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.002 · Cited by 222
Metadata
- Authors
- Schuch, R., Khan, B. K., Raz, A., Rotolo, J. A., & Wittekind, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-07
- Volume
- 61
- Issue
- 7
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2611698472
- Cited by
- 164
- References
- 3
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent. https://app.cochat.ai/papers/10.1128/aac.02666-16
- The paper
- Schuch, R., Khan, B. K., Raz, A., Rotolo, J. A., & Wittekind, M. (2017). Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02666-16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.